AI will benefit in that it
(i) produces more accurate results,
(ii) provide quicker turn-around time,
(iii) cut down human labour costs (but some level of human expertise is still required)
Where I think AI will make a difference is with the distributorship agreement with EnvoyAI and any partners.
It gives RHT a competitive advantage.
Q4 19 marks the about 9 mths since FDA approval and the EnvoyAI agreement. We should see some benefits trickling through but I think Q4 19 and Q1 2020 results will be the most exciting. As the clinical trials are approved and FerriSmart is used we should see a vast change on revenue.
What i like are these statements:
"the addition of a further 60 hospitals and imaging centresusing Resonance Health services either commercially or inclinical trials; and"
"Clinical trial work won this financial year resulted in a combined total dollar value of approximately US$1,530,200 (see ASXannouncements dated 23 August 2018, 29 October 2018, and 31 October 2018)."
